Nils P. Nickel

Dr. Nils P. Nickel


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
NNNils P. Nickel
Nils P. Nickel
GGGian M. Galura
Gian M. Galura
MZMarc J. Zuckerman
Marc J. Zuckerman
MHM. Nawar Hakim
M. Nawar Hakim
HAHaider Alkhateeb
Haider Alkhateeb
GHGustavo A. Heresi
Gustavo A. Heresi
Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi‐organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure produces congestive hepatopathy, a disease state that has direct consequences on liver biochemistry, histology, and systemic glucose and lipid metabolism. This article aims to summarize the consequences of congestive hepatopathy with an emphasis on liver biochemistry, histology, and PAH‐targeted therapy. Furthermore, PAH‐specific changes in glucose and lipid metabolism will be discussed.

3 April 2023 in Pulmonary Circulation
Verified
Journal Article
Open access
KFKahtan Fadah
Kahtan Fadah
JRJose B. Cruz Rodriguez
Jose B. Cruz Rodriguez
HAHaider Alkhateeb
Haider Alkhateeb
DMDebabrata Mukherjee
Debabrata Mukherjee
HGHernando Garcia
Hernando Garcia
NNNils P. Nickel
Nils P. Nickel
Pulmonary arterial hypertension (PAH) is a cardiovascular disease with high mortality rate. Current guidelines propose initiation and escalation of PAH‐targeted treatment based on a goal‐directed approach targeting hemodynamic, functional, and biochemical variables. This approach has been successfully validated in large Caucasian cohorts. However, given the low number of Hispanic patients enrolled in large PAH trials and registries, it is unknown if the same prognostic tools can be applied to this patient population. We analyzed a single‐center outpatient cohort that consisted of 135 Hispanic patients diagnosed with PAH. Baseline characteristics were calculated based on COMPERA, COMPERA 2.0 and REVEAL 2.0 risk scores before the initiation of PAH‐targeted therapies. The survival rate at 1 year after diagnosis was 88% for the entire cohort. The three established risk scores to predict PAH outcomes yielded similar results with reasonable discrimination of mortality in the different risk strata (all p < 0.001). Hispanic patients with PAH have a high mortality rate. Our analysis suggests that guideline proposed risk assessment at baseline yields important prognostic information in this patient population.

3 December 2022 in International Journal of Angiology
Verified
Journal Article
Closed access
PDF file
EZEmily Zientek
Emily Zientek
KTKelsey Talkington
Kelsey Talkington
JGJoshua Gardner
Joshua Gardner
YGYi Guo
Yi Guo
DMDebabrata Mukherjee
Debabrata Mukherjee
NNNils P. Nickel
Nils P. Nickel
The use of low-dose tissue plasminogen activator (tPA) in Hispanic patients with submassive pulmonary embolism (PE) is understudied.The purpose of this study is to explore the use of low-dose tPA in Hispanic patients with submissive PE compared with counterparts that received heparin alone.We retrospectively analyzed a single-center registry of patients with acute PE between 2016 and 2022. Out of 72 patients admitted for acute PE and cor pulmonale, we identified six patients that were treated with conventional anticoagulation (heparin alone) and six patients who received low-dose tPA (and heparin afterward). We analyzed if low-dose tPA was associated with differences in length of stay (LOS) and bleeding complications.Both groups were similar in regard to age, gender, and PE severity (based on Pulmonary Embolism Severity Index scores). Mean total LOS for the low-dose tPA group was 5.3 days, compared with 7.3 days in the heparin group (p = 0.29). Mean intensive care unit (ICU) LOS for the low-dose tPA group was 1.3 days compared with 3 days in the heparin group (p = 0.035). There were no clinically relevant bleeding complications documented in either the heparin or the low-dose tPA group.Low-dose tPA for submassive PE in Hispanic patients was associated with a shorter ICU LOS without a significant increase in bleeding risk. Low-dose tPA appears to be a reasonable treatment option in Hispanic patients with submassive PE who are not at high bleeding risk (<5%).

17 January 2022 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
JMJoscilin Mathew
Joscilin Mathew
NNNils P. Nickel
Nils P. Nickel

14 October 2021 in Cureus
Verified
Journal Article
Open access
AOAndrew J. Ortega
Andrew J. Ortega
SGSayed Reshad Ghafouri Ghafouri
Sayed Reshad Ghafouri Ghafouri
LVLynn Vu
Lynn Vu
BEBrian Edwards
Brian Edwards
NNNils P. Nickel
Nils P. Nickel
Cefepime is a fourth-generation, cephalosporin antibiotic commonly used as a first-line empirical treatment in a wide range of bacterial infections. It is predominantly excreted renally; therefore, a reduction in kidney function allows for the accumulation of cefepime to potentially toxic levels. Here we present a case of cefepime-induced encephalopathy (CIE) in a 67 years old male patient with advanced-stage renal insufficiency and cirrhosis who was admitted to our hospital for altered mental status (AMS). The patient was initially treated for hepatic encephalopathy (HE) given an elevated ammonia level (105 mu g/dL), which had significantly improved. He was also placed on intravenous (IV) cefepime for Pseudomonas bacteremia. Four days later, the patient became drowsy and confused. A detailed workup for secondary causes of AMS was performed however no significant acute abnormalities were detected. The ammonia level remained within the normal range. There was no acute intracranial pathology reported on a head computerized tomography (CT). Furthermore, an electroencephalograph (EEG) was obtained which showed generalized periodic discharge with a tri-phasic wave pattern suggesting non-convulsive status epilepticus (NCSE). CIE was suspected at that point and cefepime administration was stopped. Following cefepime discontinuation, there was a remarkable improvement in the patient's mental status for several days after cefepime discontinuation that supported the diagnosis of CIE in our patient. Although the exact pathophysiology is unclear, CIE should be suspected in elderly patients, patients with renal dysfunction, and critical illness. Meanwhile, liver dysfunction can be an additional risk factor for CIE as it increases the permeability of the blood-brain barrier (BBB), altered neurotransmission, and neuro-inflammation.

19 May 2025 in International Journal of Angiology
Verified
Journal Article
Closed access
PDF file
AKAditi Kothari
Aditi Kothari
ADAlok K. Dwivedi
Alok K. Dwivedi
DMDebabrata Mukherjee
Debabrata Mukherjee
MRManu Rajachandran
Manu Rajachandran
NNNils P. Nickel
Nils P. Nickel
There is an underrepresentation of Hispanic patients in studies examining right ventricular (RV) function in acute pulmonary embolism (PE). Although the prognostic value of RV dysfunction in acute PE is well established, there is no generalized definition of RV dysfunction. In this study, our aim was to identify echocardiographic parameters that predict short-term mortality in Hispanic patients with intermediate-risk acute PE. This study aimed to determine clinical and echocardiographic predictors of mortality in Hispanic patients with intermediate-risk PE. We retrospectively studied a cohort of Hispanic patients with acute PE diagnosed on computed tomography angiography and classified as intermediate-risk based on either imaging findings or biomarker elevation. We identified 419 patients. The mean age was 58, and 53% were females. Forty (9.5%) patients died during the 30-day follow-up. Non-survivors had a higher Pulmonary Embolism Severity Index (PESI) score (101 ± 19.4, p < 0.001), a higher incidence of diabetes, chronic kidney disease, end-stage renal disease, malignancy, and previous history of venous thromboembolism. On echocardiogram, non-survivors had an increased right ventricular end-diastolic area (32.7 ± 9 cm2), higher right ventricular to left ventricular ratio (RV/LV, 0.75 ± 0.15), elevated right ventricular systolic pressure (RVSP, 42.4 ± 8.24), reduced right ventricular fractional area change (RVFAC, 24.03 ± 7.6), and reduced lateral tricuspid annular peak systolic velocity (TR max Vel S′, 9.39 ± 2.2). In Hispanic patients with acute intermediate-risk PE, increased RV afterload (RVSP), RV dilation (RVDa, RV/LV ratio), and reduced RV systolic function (tricuspid annular plane systolic excursion, S′, RVFAC) are the most important predictors of poor short-term outcome. This study was approved by the Texas Tech University Health Sciences Science Center El Paso, institutional review board (E22067). Article published online: 19 May 2025 © 2025. International College of Angiology. This article is published by Thieme. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA